Bionano Genomics Q3 2026 Results: Net Loss of $6.45M, Loss Narrows
Bionano Genomics reported total revenue of $8.28 million for the third quarter of 2026, a 12% increase year-over-year, while narrowing its quarterly net loss to $6.45 million compared to $8.50 million in 2025. The company's cash position remains tight, with total cash, cash equivalents, and investments decreasing significantly from $19.27 million at the end of 2025 to $8.17 million as of September 30, 2026.
- Key figure
- Net loss $6.45M